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Finally, as with any emerging technology it is important that 
we understand its clinical ramifications: How is the use of the 
MC method likely to impact patient outcomes? Methods 
toward clearly addressing this question are fraught with 
challenges. We will summarize the approaches being used in 
evaluating the clinical impact of MC-based photon dose 
calculations and will discuss the associated issues.  
   
 
Teaching Lecture: Role, clinical application and validation 
of deformable image registration and dose mapping tools  
 
 
SP-0586   
Role, clinical application and validation of deformable 
image registration and dose mapping tools 
E. M. Vasquez-Osorio1 
1Erasmus Medical Center Rottterdam, Radiation Oncology, 
Rotterdam, The Netherlands 
   
 
Teaching Lecture: From ‘humble’ beginnings to the vision 
of 2020 for RTTs  
 
 
SP-0587   
From 'humble' beginnings to the vision of 2020 for RTTs 
M. Coffey1 
1TCD Division of Radiation Therapy, Radiotherapy, Dublin, 
Ireland Republic of  
 
In 1916 Dr. C. Thurston Holland addressed the role of the 
professionals that we now know as RTTs in the following 
terms:  “The place of these people…..is merely that of 
assistants.  They work directly under medical control, accept 
no responsibilities of any kind, and merely do as they are 
told” 
Radiotherapy practice is unrecognizable in 2015 when 
compared to the time when this statement was made.  
 Almost a century later RTTs have largely become recognized 
as professionals who contribute significantly to the activities 
carried out in our radiotherapy departments.   However 
achieving professional recognition has been a long and 
contentious road that despite gathering momentum in recent 
decades and has a long way to go.    
Being a part of the radiotherapy team in the current 
environment is stimulating, exciting and rewarding and the 
opportunities post 2020 are immense.  In this rapidly 
changing environment professional practice must be 
constantly adapted to keep, not only abreast, but ahead of 
the scientific and technological developments.   RTTs must 
review and reconsider the way they practice and be prepared 
to move from the traditional to the innovative.  RTTs are 
rapidly becoming the drivers of their own practice, have met 
the challenges and adapted readily to the spectrum of 
technology now in routine use and must continue to do so.     
What does the future hold?  Adaptive planning will be 
routine, biological treatment planning will be coming into 
practice, new molecular approaches will be coming on 
stream all leading to individualized treatment for patients.  
Choice of treatment plan based on image evaluation will be 
normal practice for the RTT and will bring about a changing 
relationship with their patient and other members of the 
team.   For RTTs the challenges of 2020 are immense and we 
must also position ourselves to be ready to meet these 
challenges and provide care to our patients consistent with 
the ESTRO Vision Statement: “challenges of individualised 
patient care will be achieved by integrating new clinical and 
preclinical evidence from biology, molecular/functional 
imaging and the use of new systemic agents together with 
the delivery of high precision radiation therapy in a safety 
aware environment” 
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At present, standard RT volume is the whole prostate gland, 
as is the case of radical prostatectomy. This is due to 2 
factors: 1) multifocal intraprostatic spread of prostate cancer 
and 2) impossibility to identify tumor foci on the standard RT 
planning imaging modality (computer tomography, [CT]). 
However, the whole organ one-dose level RT is rarely used in 
solid tumors. Localized approach, i.e. RT to tumor site only 
or to the whole organ followed by boost to tumor site is 
common. Several reports have demonstrated that 
 dominant/biggest intraprostatic lesion (DIL) is the major site 
of recurrence after prostate cancer RT. Introduction of new 
imaging technologies (Positron Emission Tomography [PET], 
Single PET [SPECT], extended transrectal ultrasound [TRUS]-
biopsies, Doppler ultrasound and multiparametric magnetic 
resonance [mpMRI]) has allowed to identify DIL. According to 
the international consensus, mpMRI including T2-weighted 
imaging (T2WI), diffusion weighted imaging (DWI) and 
dynamic contrast enhanced (DCE) images represents the 
optimal current prostate imaging1. This opens 2 new 
scenarios: 1) boosting DIL concomitantly/sequentially to the 
whole prostate RT and 2) partial prostate irradiation (PPI) 
i.e. primary focal RT. 
As far as DIL boosting is concerned, up till now 11 series (833 
pts) have been published2. Both external beam RT (EBRT) and 
brachytherapy (BRT) have been used as boost, with 8 Gy (3-
35Gy) or 150% (130-155%) boost/whole prostate dose, 
respectively. DIL boost has been studied mainly in the 
conventional fractionation (IMRT + simultaneous integrated 
boost [SIB]), and only recently DIL SIB for extreme 
hypofractionation has been evaluated. 5 planning studies (3 
 EBRT and 2 BRT, 65 pts) have been published, comparing 
different RT techniques (see fig. as example) and different 
dose schemes (128% mean ratio boost/whole prostate dose, 
range 110-150%). 2 studies on patient series have been 
published (76 pts) using EBRT or high-dose-rate (HDR) BRT 
(112% mean ratio between boost/whole prostate dose, range 
108-116%). Delivering DIL SIB in extreme hypofractionation 
appears feasible but should be approached with caution. 
Clinical value of DIL dose escalation is unknown. Ongoing 
trials like FLAME, HEIGHT, DELINEATE, NCT01409473 and 
NCT01913717 will contribute to further assessment of 
boosting DIL. 
Primary focal therapy has been explored for 20 years now 
and more than 2000 patients have been treated3 (mainly with 
cryosurgery, high-intensity ultrasound [HIFU], photodynamic 
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therapy [PDT], photothermal therapy, radiofrequency 
interstitial tumor ablation [RITA], focal laser ablation [FLA]) 
but only limited data have been published on the primary 
PPI. From the technique point of view, PPI is now feasible 
with focal BRT and EBRT. The majority of series include both 
low-dose-rate (LDR) and HDR BRT and only recently 
feasibility of PPI by EBRT has been reported4,5. According to 
the international&interdisciplinary panel consensus6, the 
selection criteria for focal therapy include unilateral low-to-
intermediate risk disease < cT2a (prostate size, tumor 
volume, and topography depend on the ablative technology 
used). As for any other focal therapy, focal RT remains 
investigational until numerous questions are answered: initial 
diagnostic tools to identify DIL (imaging, biopsy), technical 
parameters of focal therapy, follow-up exams and 
scheduling, tumor control (patterns of failure) and toxicity 
profile including erectile dysfunction and quality of life (in 
particular, compared to the whole prostate therapy), 
response evaluation and failure definition (nadir+2 is used, 
but in some series biopsy is routinely performed), salvage 
therapy and cost-benefit. Ongoing trials like NCT013549951 
and NCT00807820 will contribute to further assessment of 
PPI. 
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Purpose/Objective: Image-guided IMRT (IG-IMRT) is 
associated with significant dose reductions to organs at risk 
(OAR) compared to 3D-conformal radiotherapy (3D-CRT) in 
prostate cancer patients. However, clinical data identifying 
the benefits of IG-IMRT in patients treated in daily practice 
are scarce. We compared dose distributions and acute 
gastrointestinal (GI) and genitourinary (GU) toxicity levels of 
prostate cancer patients treated to 78 Gy (39x 2 Gy) with 
either IG-IMRT or 3D-CRT.  
Materials and Methods: A total of 215 patients treated to 78 
Gy with 3D-CRT within a dose escalation trial (1997-2003) and 
260 patients treated with IG-IMRT to 78 Gy in the standard 
arm of a hypofractionation trial (2007-2010) are included in 
this analysis. Applied margins were 10mm (3D-CRT) and 5-
8mm (IG-IMRT), and both used 0 mm towards the rectum for 
the 10 Gy boost. Dose surface histograms of anorectum, anal 
canal and bladder were compared. Furthermore, in both 
trials identical toxicity questionnaires were prospectively 
distributed at baseline, at fraction 20 and 30 and 90 days 
after treatment. Slightly modified RTOG grade ≥1, grade ≥2 
and ≥3 toxicity endpoints were derived directly from the 
patient-reported questionnaires. Univariate (UV) and 
multivariate (MV) binary logistic regression was performed. 
Results: IG-IMRT resulted in significant lower median volumes 
receiving 5- 75Gy (all p values <0.001) for anorectum (Figure 
1a), anal canal and bladder. The mean dose to the anorectum 
was 34.4 Gy vs. 47.3 Gy, 23.6 Gy vs. 44.6 Gy for the anal 
canal and 33.1 Gy vs. 43.2 Gy for the bladder (all p<0.001). 
Acute toxicity reached a maximum at fraction 30 for most 
endpoints, as shown for proctitis grade ≥2/ ≥3 in Figure 1b. 
After adjusting for risk factors at MV analysis, IG-IMRT 
resulted in significantly lower overall GI grade ≥2 RTOG 
toxicity (29% vs. 49%, p=0.002, odds ratio (OR) 0.49) and 
overall GU grade ≥2 toxicity (38% vs. 48%, p=0.009, OR 0.59). 
Significantly lower incidences were reported for the 
endpoints abdominal cramps (34% vs. 46%), tenesmus (49% vs. 
62%), mucous discharge (47% vs. 62%), grade ≥2 proctitis (27% 
vs. 44%), stool frequency ≥6/day (8% vs 19%), and urinary 
frequency ≥12/day (19% vs. 30%) (p values 0.002-0.028). 
Comparable incidences (p values >0.05) were found for 
incontinence (both 27%), diarrhea (both 14%), rectal blood 
loss (12% vs. 20%) and nycturia ≥5/night (23% vs. 27%).  
 
